Pancreatic Cancer Research

ResearcherThe University of MelbourneActive in the last 2 years

Hong Zhen He

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-2342-8750; OpenAlex author ID A5022302377. Sources: OpenAlex.

Their work

Papers
26 (first author 4, last author 15)
Trials
0
Grants
0
Labs led
1
Collaborators
20
Papers, trials and grants by year

2013: 1 paper · 2014: 1 paper · 2015: 1 paper · 2016: 2 papers · 2017: 1 paper · 2018: 3 papers · 2019: 3 papers · 2020: 2 papers · 2021: none · 2022: 2 papers · 2023: 2 papers · 2024: 1 paper · 2025: 5 papers · 2026: 2 papers

Papers 26

  1. A Streamlined Protocol for Developing a Clinicopathological Prediction Model for Patient Survival of Post-Resection of Pancreatic Cancer. Last author DOI 10.1002/cam4.71535↗
  2. Thousand-And-One Kinase 3 in Pancreatic Ductal Adenocarcinoma Stemness, Microenvironment and Therapy Resistance. First author DOI 10.3390/ijms27146290↗
  3. Knockout of p21-Activated Kinase 4 Stimulates MHC I Expression of Pancreatic Cancer Cells via an Autophagy-Independent Pathway. Last author DOI 10.3390/cancers17030511↗
  4. The Effects of PAK-Regulated Tumour Vasculature on Gemcitabine Response of Pancreatic Cancer. Last author DOI 10.3390/cancers17213434↗
  5. Evaluation of Nanoparticle-Based Plasma Enrichment on Individuals with Primary and Metastatic Pancreatic Cancer. Last author DOI 10.3390/cancers17233765↗
  6. Targeting PAK1 or PAK4 Uncovers Different Mechanisms of Vascular Reprogramming in Pancreatic Cancer. Last author DOI 10.3390/cells14221806↗
  7. P-21 Kinase 1 or 4 Knockout Stimulated Anti-Tumour Immunity Against Pancreatic Cancer by Enhancing Vascular Normalisation. Last author DOI 10.3390/ijms26178357↗
  8. A Tumor Homing Peptide-Linked Arsenic Compound Inhibits Pancreatic Cancer Growth and Enhances the Inhibitory Effect of Gemcitabine. Co-author DOI 10.3390/ijms252111366↗
  9. PAK in Pancreatic Cancer-Associated Vasculature: Implications for Therapeutic Response. Last author DOI 10.3390/cells12232692↗
  10. CXCL5 knockdown attenuated gemcitabine resistance of pancreatic cancer through regulation of cancer cells and tumour stroma. Last author PMID 37193135↗
  11. The trilogy of P21 activated kinase, autophagy and immune evasion in pancreatic ductal adenocarcinoma. Last author DOI 10.1016/j.canlet.2022.215868↗
  12. A novel PAK4 inhibitor suppresses pancreatic cancer growth and enhances the inhibitory effect of gemcitabine. Co-author DOI 10.1016/j.tranon.2021.101329↗
  13. Inhibition of PAK1 suppresses pancreatic cancer by stimulation of anti-tumour immunity through down-regulation of PD-L1. Last author DOI 10.1016/j.canlet.2019.12.020↗
  14. Cannabinoids Inhibited Pancreatic Cancer via P-21 Activated Kinase 1 Mediated Pathway. Co-author DOI 10.3390/ijms21218035↗
  15. Potential Use of Cannabinoids for the Treatment of Pancreatic Cancer. First author DOI 10.1089/pancan.2018.0019↗
  16. Antitumor effects of all-trans retinoic acid and its synergism with gemcitabine are associated with downregulation of p21-activated kinases in pancreatic cance… Last author DOI 10.1152/ajpgi.00344.2018↗
  17. PAK inhibition by PF-3758309 enhanced the sensitivity of multiple chemotherapeutic reagents in patient-derived pancreatic cancer cell lines. Last author PMID 31312349↗
  18. The PAK Inhibitor PF-3758309 Promotes the Inhibitory Effects of Multiple Chemotherapeutic Reagents on Patient-Derived Pancreatic Cancer Cell Lines Co-author DOI 10.20944/preprints201809.0322.v1↗
  19. p21-activated kinase signalling in pancreatic cancer: New insights into tumour biology and immune modulation. Last author DOI 10.3748/wjg.v24.i33.3709↗
  20. Inhibition of p21 activated kinase enhances tumour immune response and sensitizes pancreatic cancer to gemcitabine. Last author DOI 10.3892/ijo.2017.4193↗
  21. Inhibition of group 1 p21-activated kinases suppresses pancreatic stellate cell activation and increases survival of mice with pancreatic cancer. Co-author DOI 10.1002/ijc.30615↗
  22. FRAX597, a PAK1 inhibitor, synergistically reduces pancreatic cancer growth when combined with gemcitabine. First author DOI 10.1186/s12885-016-2057-z↗
  23. Glaucarubinone Combined with Gemcitabine Improves Pancreatic Cancer Survival in an Immunocompetent Orthotopic Murine Model. Co-author DOI 10.3109/08941939.2016.1160167↗
  24. The role of p21-activated kinases in pancreatic cancer. First author DOI 10.1097/mpa.0000000000000276↗
  25. Glaucarubinone and gemcitabine synergistically reduce pancreatic cancer growth via down-regulation of P21-activated kinases. Last author DOI 10.1016/j.canlet.2014.01.001↗
  26. Comparison of two syngeneic orthotopic murine models of pancreatic adenocarcinoma. Co-author DOI 10.3109/08941939.2013.797057↗

Closest collaborators

The 20 strongest of 20 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Mehrdad Nikfarjam · 26 shared papers, 2013–2026 · strength 4.68
  2. Ching‐Seng Ang · 7 shared papers, 2022–2025 · strength 1.77
  3. Yi Ma · 6 shared papers, 2022–2026 · strength 1.67
  4. Arian Ansardamavandi · 4 shared papers, 2023–2025 · strength 1.15
  5. Kai Wang · 6 shared papers, 2018–2020 · strength 0.68
  6. James Tai · 1 shared paper, 2026 · strength 0.43
  7. Dannel Yeo · 6 shared papers, 2013–2017 · strength 0.38
  8. Kai Wang · 2 shared papers, 2018–2023 · strength 0.27
  9. Yang Yang · 2 shared papers, 2020 · strength 0.23
  10. Nien‐Hung Lee · 1 shared paper, 2023 · strength 0.18
  11. Ashleigh Parkin · 2 shared papers, 2018–2019 · strength 0.18
  12. Jennifer Man · 2 shared papers, 2018–2019 · strength 0.18
  13. Marina Pajic · 2 shared papers, 2018–2019 · strength 0.18
  14. Dong Li · 1 shared paper, 2022 · strength 0.17
  15. Golnaz Sharafi · 1 shared paper, 2019 · strength 0.16
  16. David Herrmann · 1 shared paper, 2020 · strength 0.10
  17. Paul Timpson · 1 shared paper, 2020 · strength 0.10
  18. Phoebe A. Phillips · 1 shared paper, 2017 · strength 0.09
  19. Christopher Christophi · 2 shared papers, 2013–2014 · strength 0.08
  20. Andrew M. Lowy · 1 shared paper, 2016 · strength 0.07

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.